Nandrolone Bloodwork: Preventing Deca Dick with Right Labs

"Deca dick" has scared bodybuilders off nandrolone for decades. But it is a preventable problem when you monitor the right markers at the right times. The issue is that most users check the wrong things, use the wrong lab methodology, and reach for the wrong interventions when something feels off.

The result is predictable: athletes crash their estradiol trying to fix a prolactin problem, or they blame prolactin when the real issue is a poor testosterone-to-nandrolone ratio. Some run cabergoline prophylactically when their prolactin is perfectly normal. Others sit on elevated prolactin for months because they trusted a standard immunoassay that was being inflated by nandrolone cross-reactivity.

This guide fixes those mistakes. Here is what to measure, when to measure it, and what to actually do with the results.

Why "deca dick" is a bloodwork problem, not a deca problem

The compound itself is not the villain. Nandrolone decanoate has a 40-year clinical history as a treatment for anaemia, muscle-wasting disease, and osteoporosis. The sexual dysfunction side effect emerges predictably from identifiable, measurable, correctable biochemical conditions. If your bloodwork is right, your risk drops sharply.

The real cause: testosterone-to-nandrolone ratio and DHN vs DHT

The biochemistry here is counterintuitive but well-documented. When testosterone passes through 5-alpha reductase, it converts to dihydrotestosterone (DHT), a potent androgen at penile tissue. When nandrolone passes through the same enzyme, it converts to dihydronandrolone (DHN), which is materially weaker at androgen receptors than DHT (Toth & Zakar, 1985).

This is the mechanism that underpins deca dick. Nandrolone competes with testosterone for 5-alpha reductase. When nandrolone dose is high relative to testosterone, more of that enzymatic capacity converts nandrolone to DHN rather than testosterone to DHT. The net effect is reduced androgenic tone at penile tissue, exactly where you need it for erectile function.

Clark, Harrold and Fast demonstrated this in a controlled animal study: nandrolone administered alongside intact endogenous testosterone showed minimal sexual behavior effects (Clark et al., 1997). The same compound administered as the primary androgen, without adequate testosterone, produced the expected dysfunction. Esposito and colleagues confirmed the HPG suppression pathway in a 2023 systematic review of AAS-induced erectile dysfunction (Esposito et al., 2023).

The practical rule that comes out of this literature is one most experienced nandrolone users already know: keep your testosterone dose at or above your nandrolone dose. A 1:1 ratio is the minimum. Many coaches and clinicians prefer 2:1 (test:nandrolone). This is not just gym lore; it reflects genuine pharmacology.

5-alpha reductase inhibitors (finasteride, dutasteride) make this worse. They are occasionally used to prevent hair loss on nandrolone cycles, but they reduce DHT conversion without affecting DHN, further tilting the androgenic balance at genital tissue in the wrong direction. If you are running a 5-ARI alongside nandrolone, account for this.

Prolactin, progesterone, or both?

Prolactin is a secondary mechanism in deca dick, relevant mainly at higher doses and in susceptible individuals. Nandrolone suppresses LH and FSH within four days of the first injection (Garevik et al., 2016), which alone is enough to create a hormonal environment where sexual function suffers. Compounding this, nandrolone alters kappa opioid receptor density in the hypothalamus (Magnusson et al., 2009), reducing dopaminergic tone and allowing prolactin to rise.

The hyperprolactinemia-ED link is clinically established, with case reports demonstrating resolution of ED after prolactin normalization (Muadi & Sanchez, 2021). Emphasis on elevated: a mild prolactin reading within the reference range does not warrant intervention. The error is treating prolactin as the primary culprit when the ratio issue has not been addressed first.

The progesterone narrative deserves a direct response. Some community sources frame 19-nor compounds as "progestenic" and blame this progestin activity for elevated prolactin. The pharmacology runs the opposite direction. Progestins suppress prolactin at the pituitary (Giguere et al., 1982). Lynestrenol, a 19-nortestosterone derivative, significantly decreases prolactin in clinical studies (Sitruk-Ware et al., 1985). The prolactin elevation seen with nandrolone occurs via hypothalamic opioid receptor modulation, not via pituitary progestogenic action. Serum progesterone is not a useful marker to chase on a nandrolone cycle. Prolactin is.

The lab interference trap: nandrolone inflates your testosterone reading

Click to expand

This is the most underappreciated issue in nandrolone monitoring, and it affects both testosterone and estradiol readings.

Standard immunoassays are antibody-based tests optimised for detecting testosterone in the absence of other steroids. Nandrolone shares the 17-beta hydroxyl group and the C4-en-3-one A-ring configuration with testosterone; it differs only at the C-19 position, where it lacks a methyl group. That structural similarity is enough to trigger material cross-reactivity in many immunoassays.

Krasowski et al. found that several AAS may produce clinically significant false positives on the testosterone immunoassay (Krasowski et al., 2014). La'ulu et al. documented accuracy ranging from 79.2% to 149.2% across five automated testosterone immunoassays (La'ulu et al., 2018). In practice, this means your lab report could show 800 ng/dL testosterone when your actual testosterone is 500 ng/dL and the remaining signal is nandrolone cross-reactivity.

That matters enormously for clinical decision-making. If you are running 300 mg/week of nandrolone decanoate alongside 200 mg/week of testosterone enanthate, you want to know whether your testosterone is genuinely adequate, not whether nandrolone is inflating the reading.

Order LC-MS/MS for accurate testosterone AND estradiol

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) physically separates steroid molecules before quantification. Nandrolone cannot confound the testosterone measurement because the two molecules are resolved chromatographically before the detector ever sees them. Researchers studying testosterone pharmacokinetics in the presence of nandrolone have used LC-MS/MS exclusively for accurate steroid quantification (Iyer et al., 2017).

The same problem applies to estradiol. Standard estradiol immunoassays were validated for estradiol-only samples. Add nandrolone metabolites and you can get spuriously elevated or suppressed readings depending on the assay. If you are adjusting your aromatase inhibitor dose based on an immunoassay estradiol while on nandrolone, you may be chasing an artefact. Request sensitive E2 by LC-MS/MS. Some labs call this "ultrasensitive estradiol" or "estradiol LC/MS."

For more on why estradiol measurement methodology matters, see Estradiol on TRT: What Your Lab Report Actually Means.

Prolactin monitoring: the marker that predicts deca dick

Prolactin is the one hormone you cannot infer from symptoms alone. Moderate hyperprolactinemia and low estradiol produce almost identical symptoms: low libido, difficulty achieving or maintaining erections, reduced sexual motivation. Without a prolactin measurement, you cannot distinguish between them, and the correct intervention for each is the opposite of the other.

Check prolactin at week 4 of your nandrolone cycle. This is the window where prolactin peaks before stabilising, and it gives you time to intervene before symptoms become established. Qasim Ali et al. confirmed elevated prolactin in AAS users including those using nandrolone, with the elevation present across a range of doses (Qasim Ali et al., 2024).

One practical note on timing: prolactin is sensitive to stress, physical exertion, and sexual activity in the hours preceding the blood draw. Draw your sample in the morning, fasted, after sitting quietly for 15-20 minutes. Avoid sex and intense exercise in the 24 hours before the draw if you can manage it. A single spuriously elevated reading can trigger unnecessary intervention.

P5P vs cabergoline: a threshold-based decision framework

The community debates P5P (pyridoxal-5-phosphate, the active form of vitamin B6) and cabergoline constantly, and often without reference to the evidence. Here is what the evidence actually says.

P5P's proposed mechanism is that vitamin B6 is a cofactor in dopamine synthesis (Rose et al., 1979). Since dopamine suppresses prolactin via D2 receptors, enhancing dopamine synthesis should lower prolactin. The early research was encouraging: McIntosh and colleagues showed pyridoxine restored prolactin to normal in some women with elevated prolactin (McIntosh et al., 1976). However, Brambilla and colleagues tested pyridoxine against neuroleptic-induced hyperprolactinemia and found it failed entirely to normalise prolactin in that context (Brambilla et al., 1980). Drug-induced hyperprolactinemia works by blocking D2 receptors or reducing dopaminergic tone, not by reducing the substrate available for dopamine synthesis. Adding more B6 does not help when the bottleneck is receptor blockade, not cofactor availability.

The bottom line on P5P: it may provide marginal benefit for mild functional hyperprolactinemia where the cause is suboptimal dopamine synthesis, but it is unlikely to correct nandrolone-induced prolactin elevation at therapeutic doses. It will not hurt you at 100-200 mg/day, but do not rely on it as your primary intervention.

Cabergoline is a D2-selective dopamine agonist with 80-90% effectiveness for normalising hyperprolactinemia across aetiologies (Ma et al., 2025). It is the drug of choice when prolactin is genuinely elevated and causing symptoms. The standard dose is 0.25 mg twice weekly. It is well-tolerated at this dose, and cardiac valve risk, which attracted attention at Parkinson's disease doses (3-5 mg/day), is not meaningfully elevated at PED management doses of 0.25-0.5 mg/week (Nachtigall et al., 2010).

Here is a practical decision framework based on the evidence:

Lu and colleagues found that below 50 ng/mL, pharmacological intervention was no better than placebo for subjective outcomes in some contexts (Lu et al., 2022). This does not mean you ignore prolactin below that threshold, but it contextualises the urgency. A reading of 22 ng/mL in an asymptomatic athlete with good sexual function is not a crisis.

The D2 receptor knockout mouse model makes this concrete: without functional D2 receptors, animals develop chronic hyperprolactinemia (Kelly et al., 1997). That is why nandrolone's effect on opioid receptor density, which dampens dopaminergic signalling, translates into prolactin elevation. Remove the dopamine brake and prolactin climbs.

How long prolactin stays elevated after stopping

With nandrolone decanoate, plan to retest prolactin 4-6 weeks after your last injection. The ester takes 4-6 weeks to clear completely, meaning the compound remains pharmacologically active for weeks after you stop pinning. Prolactin will not normalise until nandrolone clears.

NPP (nandrolone phenylpropionate) is faster: the ester clears in roughly 2-3 weeks. Post-cycle prolactin retest can be moved to 3-4 weeks after the last NPP injection.

Progesterone vs prolactin: clearing the confusion

Let me address this directly, because the community gets it backwards with some regularity.

19-norandrogens like nandrolone bind the progesterone receptor with significant affinity (Attardi et al., 2006). This is real pharmacology. The error is inferring from this that nandrolone therefore raises prolactin via a progestogenic mechanism at the pituitary.

In fact, progestins suppress prolactin release at the pituitary. Giguere and colleagues showed that the synthetic progestin R5020 inhibited prolactin release by 33-50% in pituitary cells (Giguere et al., 1982). Sitruk-Ware and colleagues demonstrated that lynestrenol, a 19-nortestosterone derivative closely related to nandrolone, significantly decreased prolactin in clinical subjects (Sitruk-Ware et al., 1985).

The resolution to this apparent paradox: nandrolone raises prolactin via hypothalamic opioid receptor modulation, reducing dopaminergic tone (Magnusson et al., 2009). The mechanism is not progestogenic pituitary action. It is a central, hypothalamic effect on the dopamine-prolactin axis.

The practical implication: measuring serum progesterone on a nandrolone cycle is not useful. Nandrolone does not raise serum progesterone. It activates the progesterone receptor as a ligand, but that is a receptor-level effect, not a serum hormone change. Prolactin is the one hormone that changes measurably and that you can act on.

Estradiol management on nandrolone

Nandrolone aromatises, but at roughly 20% the rate of testosterone (Payne et al., 1989). That means at 300 mg/week of nandrolone decanoate alongside 200 mg/week of testosterone, your total aromatisation burden is lower than someone running 500 mg/week of testosterone alone. Estradiol problems on nandrolone cycles typically come from the testosterone component, not the nandrolone itself.

Why crashing E2 with an AI makes everything worse

This is the single most common mistake in managing deca dick. An athlete notices erectile dysfunction, assumes it must be estrogen-related (because estrogen causes sexual dysfunction in the common oversimplified framing), reaches for anastrozole, drives estradiol into the floor, and wonders why things got worse.

Estradiol deficiency is independently associated with loss of libido, reduced fertility, joint pain, and bone loss (Gustafsson, 2006). It also directly impairs HDL efflux capacity (Menezes et al., 2018). Crashing E2 to manage deca dick is a diagnostic error: an AI does not reduce prolactin, does not fix the DHN/DHT ratio, and does not address the HPG suppression that nandrolone causes. It just removes a hormone you need.

The target range on nandrolone cycles remains 20-40 pg/mL for estradiol, measured by LC-MS/MS. Use an AI only if E2 is genuinely elevated and symptomatic. If your estradiol is 38 pg/mL and you have erectile dysfunction, the E2 is almost certainly not the problem.

Estradiol and SHBG on nandrolone

Nandrolone suppresses SHBG substantially. Lower SHBG means more free estradiol even when total estradiol is moderate. An SHBG of 15 nmol/L with estradiol at 35 pg/mL gives you a higher free E2 than an SHBG of 40 nmol/L at the same total E2. Track both together. For the deeper explanation of free estradiol, read Estradiol on TRT.

Deca vs NPP: how ester length changes your monitoring timeline

Click to expand

Nandrolone decanoate and nandrolone phenylpropionate are the same base compound attached to different esters. The pharmacological effects at equivalent doses are identical. The ester only determines how quickly the compound releases and clears.

Nandrolone decanoate has a depot release half-life of approximately 6 days, with peak concentrations reached at 30-72 hours after injection (Wijnand et al., 1985). Steady state for weekly injections occurs around 6 weeks. Bagchus and colleagues showed a half-life range of 7-12 days in the clinical context (Bagchus et al., 2005).

NPP has a much shorter half-life, typically cited at 2-3 days for the ester release phase. Steady state arrives around 3 weeks. Belkien et al. conducted the definitive head-to-head comparison of these two esters and confirmed that NPP reaches stable concentrations significantly faster (Belkien et al., 1985).

This difference has real implications for your monitoring calendar and for managing side effects if they emerge.

When to draw blood for each ester

For nandrolone decanoate (Deca): Your first meaningful blood panel is at week 6-8, when steady state has been reached. Drawing at week 2 or 3 tells you very little about your on-cycle values because you are still in the uptitration phase.

For NPP: First meaningful bloodwork at week 3-4. You reach steady state faster and can intervene sooner if prolactin or other markers are off.

The NPP advantage for side effect management: If deca dick or other side effects emerge, NPP clears in 2-3 weeks after stopping. Nandrolone decanoate takes 4-8 weeks to clear. For athletes using nandrolone for the first time, NPP is the ester that lets you learn your response without committing to months of pharmacological exposure.

The complete monitoring calendar

Use this as your baseline framework and adjust based on individual response. If symptoms emerge at any point, draw blood immediately rather than waiting for the scheduled timepoint.

Nandrolone decanoate (Deca) monitoring schedule

NPP users: shift the calendar forward

Draw your week 4 prolactin check at week 3. Move the post-cycle retest to 4-5 weeks after your last injection rather than 6-8 weeks.

For the comprehensive bloodwork guide that explains each marker on this panel, see The Complete Guide to Bloodwork for Bodybuilders.

Lipids, haematocrit, and kidney function on nandrolone

Nandrolone affects more than hormones and prolactin. Three additional systems deserve monitoring, particularly on longer cycles.

Nandrolone's lipid profile: least bad, but not harmless

The data here pulls in two directions. Hartgens and colleagues ran an RCT at 200 mg/week and found no significant HDL change compared to control (Hartgens et al., 2004). Kuipers et al. found 25-27% HDL reduction at 100 mg/week, with reversibility within about 6 weeks of stopping (Kuipers et al., 1991). The discrepancy comes down to dose-response and polypharmacy. Real-world nandrolone cycles are almost never nandrolone alone; when you add testosterone and other compounds, HDL drops compound with each addition. The Hartgens trial looks cleaner because of controlled conditions.

Treat nandrolone as having moderate HDL-suppressing potential, worse than low-dose testosterone but better than most orals and far better than trenbolone. Monitor fasting lipids at baseline, mid-cycle (week 8), and post-cycle. For a full breakdown of steroid-lipid interactions and interventions, see Cholesterol on Steroids.

Haematocrit and RBC monitoring

Nandrolone raises haemoglobin and haematocrit through erythropoietic stimulation. This is so reliable that nandrolone was used for decades as a treatment for anaemia in dialysis patients (Teruel et al., 1996). On a nandrolone cycle, you will see haematocrit rise.

This is less aggressive than trenbolone but still requires monitoring. Flag haematocrit at 52% for attention. At 54%, intervention is warranted: reduce dose, increase hydration, consider therapeutic phlebotomy. Running nandrolone alongside testosterone amplifies the erythropoietic effect because you now have two androgens stimulating red blood cell production simultaneously. Check haematocrit and haemoglobin at weeks 4 and 8 as a minimum. For the detailed protocol on managing elevated haematocrit, see TRT and High Haemoglobin/Haematocrit.

Kidney function: why creatinine alone is not enough

Standard creatinine is not a reliable kidney marker in athletes running anabolic steroids. Muscle mass elevates creatinine production independent of kidney function, meaning you can have a creatinine reading in the "flagged" range with perfectly healthy kidneys, or conversely a "normal" creatinine with genuine early-stage kidney stress.

Cystatin C, a small protein filtered by the glomerulus and not affected by muscle mass, is the superior marker (Ozkurt et al., 2023). Include cystatin C with eGFR at baseline, week 8, and end of cycle. Nandrolone in isolation has not been shown to be specifically nephrotoxic in clinical doses, but the combination of elevated haematocrit (increased blood viscosity), potential dehydration, and polypharmacy stacks creates conditions for kidney stress over longer cycles.

Post-cycle recovery: why nandrolone takes longer

Click to expand

Nandrolone is the compound that humbles athletes who think they know how to recover. The timeline is longer than most people expect, and the evidence for this is unambiguous.

Metabolite detection: 6+ months from a single dose

Bagchus et al. tested detection windows after a single 150 mg nandrolone decanoate injection. At 6 months post-injection, 83% of subjects still had detectable 19-norandrosterone metabolites in urine (Bagchus et al., 2005). That is one injection at a modest dose. A 12-20 week cycle at 300-600 mg/week leaves metabolites detectable for considerably longer. For athletes who compete in tested federations, the detection window for nandrolone is one of the longest among injectable compounds.

This metabolite persistence matters beyond drug testing. While the parent compound may clear in 4-8 weeks, the biological effects on LH, FSH, and Leydig cell function have a longer tail.

HPG suppression: deeper and slower to recover than testosterone alone

Singh et al. demonstrated 89% testosterone suppression within just 8 days of a single nandrolone injection (Singh et al., 2014). The WHO male contraceptive trials using depot nandrolone reported a median of 6.5 months to recover normal sperm count after stopping (WHO Task Force, 1993). Nagata and colleagues documented direct testicular toxicity in histological studies (Nagata et al., 1999), suggesting nandrolone may have peripheral Leydig cell effects beyond pure central HPG suppression.

This is the combination that makes nandrolone recovery uniquely challenging: central suppression via the hypothalamus and pituitary, plus direct testicular effects. Both pathways need to recover simultaneously.

PCT timing: wait 4-6 weeks after last Deca injection

Starting your SERM-based PCT while nandrolone decanoate is still pharmacologically active is largely ineffective. The ester is still releasing nandrolone, which continues to suppress LH and FSH. The SERM is trying to stimulate a system that is being actively suppressed.

Wait for the ester to clear: 4-6 weeks after your last nandrolone decanoate injection before beginning PCT. For NPP, that window shortens to 2-3 weeks after the last injection, which is one of NPP's practical advantages for anyone prioritising recovery speed.

Include HCG in your recovery protocol if fertility is a concern. See HCG, Fertility, and TRT for the clinical evidence on HCG-assisted recovery, and PCT Bloodwork: What to Test and When for the full post-cycle monitoring protocol.

Key takeaways

• Deca dick is primarily a testosterone-to-nandrolone ratio problem. Keep testosterone dose at or above nandrolone dose (minimum 1:1, prefer 2:1).

• Standard immunoassays for testosterone AND estradiol cross-react with nandrolone. Use LC-MS/MS for both markers throughout your cycle.

• Check prolactin at week 4. Draw in the morning, fasted, after 15-20 minutes of rest. P5P may help mild elevation; cabergoline 0.25 mg twice weekly is effective when prolactin is genuinely elevated and symptomatic.

• Do not use an aromatase inhibitor to treat deca dick. It does not address the underlying mechanisms and makes things worse by crashing estradiol.

• The progesterone narrative is inverted. Progestins suppress prolactin. Nandrolone raises prolactin via hypothalamic opioid receptor modulation, not pituitary progestogenic action.

• Use NPP if you want faster side effect management and shorter post-cycle wait times. Use nandrolone decanoate if injection frequency matters. The pharmacological effects at equivalent doses are identical.

• For Deca, wait 4-6 weeks after your last injection before starting PCT. For NPP, 2-3 weeks.

• Include cystatin C and full lipids at baseline, week 8, and end of cycle. Watch haematocrit from week 4 onwards.

---

References

Attardi, B. J., Engbring, J. A., & Gropp, D. (2006). Novel androgen analogs for male contraception. Endocrinology, 147(10), 4892-4902. DOI: 10.1210/en.2006-0330

Bagchus, W. M., Smeets, J. M., Verheul, H. A., De Jager-Van Der Veen, S. M., Port, A., & Geurts, T. B. (2005). Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. Journal of Clinical Endocrinology and Metabolism, 90(5), 2624-2630. DOI: 10.1210/jc.2004-0849

Belkien, L., Schurmeyer, T., Hano, R., Gunnarsson, P. O., & Nieschlag, E. (1985). Pharmacokinetics of 19-nortestosterone esters in normal men. Journal of Steroid Biochemistry, 22(5), 623-629. DOI: 10.1016/0022-4731(85)90161-x

Brambilla, F., Penati, G., Freni, V., & Soliveri, P. (1979). Failure of pyridoxine to affect neuroleptic-induced hyperprolactinemia in psychotic patients. Journal of Endocrinological Investigation, 2, 177-181. DOI: 10.1007/BF03350377

Clark, A. S., Harrold, E. V., & Fast, A. S. (1997). Anabolic-androgenic steroid effects on the sexual behavior of intact male rats. Hormones and Behavior, 31(1), 35-46. DOI: 10.1006/hbeh.1997.1355

Muadi, M., & Sanchez, R. (2021). Prolactinoma causing erectile dysfunction. Revista Internacional de Andrologia, 19(3), 207-210. DOI: 10.1016/j.androl.2020.05.006

Garevik, N., Rane, A., Bjornsson, E., & Strahm, E. (2016). Short term use of testosterone enanthate and nandrolone decanoate with or without co-administration of a 5alpha reductase inhibitor on pituitary hormones and spermatogenesis in young men. Drug Testing and Analysis, 8(7), 763-769. DOI: 10.1002/dta.1858

Giguere, V., Meunier, H., Veilleux, R., & Labrie, F. (1982). Direct effects of sex steroids on prolactin release at the anterior pituitary level. Endocrinology, 111(3), 857-862. DOI: 10.1210/endo-111-3-857

Gustafsson, J. A. (2006). ERbeta scientific visions translate to clinical uses. Climacteric, 9(3), 156-160. DOI: 10.1080/13697130600717364

Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). British Journal of Sports Medicine, 38(3), 253-259. DOI: 10.1136/bjsm.2003.006510

Iyer, R., Mok, S. F., Savkovic, S., Turner, L., Fraser, G., Saunders, N., & Handelsman, D. J. (2017). Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology, 5(4), 725-731. DOI: 10.1111/andr.12357

Kelly, M. A., Rubinstein, M., Asa, S. L., Zhang, G., Saez, C., Bunzow, J. R., Allen, R. G., Hnasko, R., Ben-Jonathan, N., Grandy, D. K., & Low, M. J. (1997). Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron, 19(1), 103-113. DOI: 10.1016/s0896-6273(00)80351-7

Kuipers, H., Wijnen, J. A., Hartgens, F., & Willems, S. M. (1991). Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. International Journal of Sports Medicine, 12(4), 413-418. DOI: 10.1055/s-2007-1024703

Lu, Z., Wang, Z., Liu, Y., Jin, L., Liu, B., Li, T., Tang, T., & Xu, A. (2022). Serum prolactin levels and erectile dysfunction: a systematic review and meta-analysis. Sexual Medicine, 10(4), 100536. DOI: 10.1016/j.esxm.2022.100536

Ma, Q., Jiang, M., Wu, H., Qiu, X., & Zhao, F. (2025). Cabergoline in the treatment of hyperprolactinemia: a systematic review and meta-analysis. Pituitary, 28(1), 12. DOI: 10.1007/s11102-025-01492-2

Magnusson, K., Hallberg, M., Bergquist, J., & Nyberg, F. (2009). Nandrolone decanoate administration dose-dependently affects the density of kappa opioid peptide receptors in the rat brain. Neuropeptides, 43(1), 1-5. DOI: 10.1016/j.npep.2008.10.003

Esposito, M., Salerno, M., Calvano, G., et al. (2023). Impact of anabolic androgenic steroids on male sexual and reproductive function: a systematic review. Panminerva Medica, 64(4), 516-529. DOI: 10.23736/S0031-0808.22.04677-5

McIntosh, E. N. (1976). Treatment of women with the galactorrhea-amenorrhea syndrome with pyridoxine. Journal of Clinical Endocrinology and Metabolism, 42(6), 1192-1195. DOI: 10.1210/jcem-42-6-1192

Menezes, A. R., Lavie, C. J., Gonzalez, J. N., Arce, M. O., & Johnson, R. J. (2018). Estrogen and cardiovascular risk in women. Progress in Cardiovascular Diseases, 61(5-6), 476-484. DOI: 10.1016/j.pcad.2018.10.007

Nachtigall, L. B., Valassi, E., Lo, J., McCarty, D., Olivier, P., Lawson, E. A., Matzko, M., & Klibanski, A. (2010). Cardiac valvular function in hyperprolactinaemic patients receiving cabergoline. Clinical Endocrinology, 73(3), 369-374. DOI: 10.1111/j.1365-2265.2010.03821.x

Nagata, S., Kurosawa, M., Mima, K., Nambo, Y., Fujii, Y., & Watanabe, G. (1999). Effects of anabolic steroid (19-nortestosterone) on the secretion of testicular hormones and spermatogenesis in the equine male. Journal of Reproduction and Fertility, 115(2), 373-379. DOI: 10.1530/jrf.0.1150373

Ozkurt, S., Ozakin, E., Gungor, H., & Yalcin, A. U. (2023). Assessment of renal function of bodybuilders using anabolic androgenic steroids and diet supplements. Cureus, 15(8), e43058. DOI: 10.7759/cureus.43058

Payne, A. H., Downing, J. R., & Wong, K. L. (1989). Luteinizing hormone receptors and testosterone synthesis in two distinct populations of Leydig cells. Endocrinology, 106(4), 1424-1429. DOI: 10.1210/endo-106-4-1424

Qasim Ali, M., Blankenship, M., Singh, S., & Ashraf, T. (2024). Anabolic steroid induced hyperprolactinemia: an underrecognized complication. Endocrine Practice, 30(8), 766-772. DOI: 10.1016/j.eprac.2024.05.003

Rose, D. P. (1978). The interactions between vitamin B6 and hormones. Vitamins and Hormones, 36, 53-99. DOI: 10.1016/S0083-6729(08)60982-6

Singh, A. B., Hsia, S., Alaupovic, P., Sinha-Hikim, I., Woodhouse, L., Buchanan, T. A., Becerra, N., Bross, R., Berman, N., & Bhasin, S. (2014). The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Journal of Clinical Endocrinology and Metabolism, 87(1), 136-143. DOI: 10.1210/jc.87.1.136

Sitruk-Ware, R., Varin, C., Clair, F., Maugis, H., Fermanian, J., & Mauvais-Jarvis, P. (1985). In vivo effects of progestins on prolactin secretion. Journal of Clinical Endocrinology and Metabolism, 61(3), 537-543. DOI: 10.1210/jcem-61-3-537

Teruel, J. L., Aguilera, A., Marcen, R., Navarro-Antolin, J., Ortuno, J., & Ortega, O. (1996). Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scandinavian Journal of Urology and Nephrology, 30(5), 403-408. DOI: 10.3109/00365599609182341

Toth, M., & Zakar, T. (1985). Different binding of testosterone, 19-nortestosterone and their 5 alpha-reduced derivatives to the androgen receptor of the rabbit uterus: a step towards the understanding of anabolic steroid action at the molecular level. Journal of Steroid Biochemistry, 22(4), 499-503. DOI: 10.1016/0022-4731(85)90265-1

La'ulu, S. L., Kalp, K. J., & Straseski, J. A. (2018). How low can you go? Analytical performance of five automated testosterone immunoassays. Clinical Biochemistry, 58, 15-20. DOI: 10.1016/j.clinbiochem.2018.05.004

Krasowski, M. D., Drees, D., Morris, C. S., Maakestad, J., Blau, J. L., & Ekins, S. (2014). Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clinical Pathology, 14, 33. DOI: 10.1186/1472-6890-14-33

WHO Task Force on Methods for the Regulation of Male Fertility. (1993). Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertility and Sterility, 65(4), 821-829. DOI: 10.1016/s0015-0282(16)57476-4

Wijnand, H. P., Bosch, A. M., & Donker, C. W. (1985). Pharmacokinetic parameters of 19-nortestosterone esters in healthy men. In C. Reznikoff (Ed.), Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. Springer. DOI: 10.1007/978-3-642-70439-4